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Abstract
Background: Studies have shown that DNA vaccines can induce protective immunity, which demonstrated the high 
potential of DNA vaccines as an alternative to inactivated vaccines. Vaccines are frequently formulated with adjuvants 
to improve their release, delivery and presentation to the host immune system.
Methods: The H5 gene of H5N1 virus (A/Ck/Malaysia/5858/04) was cloned separately into pcDNA3.1 + vector. The 
immunogenicity of the cloned H5 DNA vaccine was tested on SPF chickens using two different approaches. First 
approach was using H5 DNA vaccine (pcDNA3.1/H5) and the second was using H5 DNA vaccine in addition to the 
pcDNA3.1/MDP1 vaccine. Ten days old chickens inoculated three times with two weeks intervals. The spleen and 
muscle samples from chickens immunized with H5 (pcDNA3.1/H5) and H5 + MDP1 (pcDNA3.1/H5 + pcDNA3.1/MDP1) 
vaccines were collected after sacrificing the chickens and successfully expressed H5 and MDP1 RNA transcripts. The 
sera of immunized chickens were collected prior to first immunization and every week after immunization; and 
analyzed using enzyme-linked immunosorbent assay (ELISA) and hemagglutination inhibition (HI) test.
Results: Results of competitive ELISA showed successful antibody responses two weeks post immunization. The HI test 
showed an increased in antibody titers during the course of experiment in group immunized with H5 and H5 + MDP1 
vaccines. The result showed that the constructed DNA vaccines were able to produce detectable antibody titer in 
which the group immunized with H5 + MDP1 vaccine produced higher antibody comparing to H5 vaccine alone.
Conclusions: This study shows for the first time the usefulness of MDP1 as a genetic adjuvant for H5 DNA vaccine.
Background
Influenza virus can cause an acute, highly transmittable
respiratory disease, which can result in high morbidity
and mortality in both human and animals [1]. The 1997
Hong Kong outbreak of highly pathogenic avian influenza
virus (HPAI)-H5N1 showed that avian influenza is a
potential threat to human and is believed to be transmit-
ted from infected birds [2]. The Hong Kong outbreak of
avian influenza H5N1 was controlled by slaughtering 1.5
million chickens, which cost more than 245 million dol-
lars in a single month. Therefore, antivirals and vaccines
seem to be a more prospective solution to control the
outbreaks of avian influenza virus [2].
Currently, whole virus inactivated vaccines containing
HA as the main component, are the common vaccines to
prevent avian influenza. However, these vaccines require
large numbers of specific-pathogen-free embryonated
chicken eggs and about 6 months to propagate the viruses
[2]. On the other hand, this is not an ideal method to pro-
duce inactivated vaccine for highly pathogenic strains, as
the embryos are killed shortly after propagation and
require a high level of biosecurity to handle [3]. Commer-
cial vaccines have been successful in producing protec-
tive immunity against infections by homologous virus but
failed in preventing the outbreaks of heterologous virus
and occasionally been reported as a possible cause of re-
emerging outbreaks [2]. The commercially available vac-
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cines against H5N1 are inactivated whole virus vaccine
and fowlpox virus vaccine expressing the H5 gene [4].
Moreover, various recombinant vaccines against avian
influenza H5N1 virus which are able to induce different
l e v e l s  o f  p r o t e c t i v e  i m m u n i t y ,  s u c h  a s  D N A  p l a s m i d -
based vaccine, baculovirus recombinant H5 vaccine, and
reverse genetic H5 vaccine have been examined experi-
mentally [5-7].
Concurrent studies have revealed that DNA vaccines
encoding HA of influenza A virus can result in the devel-
opment of protective immune response against influenza
virus challenge in animals [8,9]. In most cases, two or
three doses of naked plasmid DNA are required to induce
immune response to the pathogen [10,11]. Nevertheless,
other studies have shown that a single dose of DNA vac-
cine can trigger protective immunity, which demon-
strated the high potential of DNA vaccines as an
alternative to inactivated vaccines [12,13]. Recently, we
have showed that the fusion of ESAT-6 of Mycobacterium
tuberculosis to H5 DNA vaccine are able to improve the
antibody titer of chickens against AIV showing the flexi-
bility of modifying the efficacy of DNA vaccine [14].
Mycobacterial DNA binding protein 1 (MDP1) is a
main cellular protein produced by Mycobacterium bovis.
The protein has both nucleic acid binding activity and
macro-molecular bio-synthesis inhibitory properties that
play key role in modulating bacterial growth [15]. Prabha-
kar et al., in 1998, revealed that DNA binding proteins
(orthologus with MDP1) may act as an immunodominant
antigen which stimulates cellular and humoral responses
presumably through TLR9 dependent pathway produc-
tion of proinflammatory cytokines [16,17] and the induc-
tion of IFN-γ production [18,19].
Hence, MDP1 may play an important role as a potential
adjuvant to boost the immunotherapeutic effects of DNA
vaccines.
Methods
Construction of recombinant DNA plasmids
Construction of eukaryotic expression plasmids were
performed by separately cloning the HA gene of H5N1
AIV (A/chicken/H5N1/5858/2004) and MDP1 gene of
Mycobacterium bovis into pcDNA3.1 + vectors (Invitro-
gen®, USA). The full length H5 gene (1707 bp) was ampli-
fied from pCR2.1/H5 (kindly provided by Nurul Hidayah,
Biologics Lab, University Putra Malaysia) using forward
and reverse primers with HindIII and BamHI sites,
respectively (Table 1). The MDP1 gene which was pro-
vided by Prof. Dr. Sohkichi Matsumoto from Department
of Bacteriology, Osaka City University Graduate School
of Medicine, Osaka, Japan; was amplified from
pcDNA3.1/MDP1 using forward and reverse primers
with HindIII and BamHI sites, respectively (Table 1). The
amplified genes of H5 and MDP1 were digested with Hin-
dIII and BamHI t o g en er a t e  c ohes ive  e nds  f or  cl oning
into pcDNA3.1. The digested products were purified by
electrophoresis and ligated into pcDNA3.1 using T4 liga-
tion system (Vivantis®, Malaysia). The constructed plas-
mids were transformed into competent Escherichia coli
Top10F' and cultured overnight for further application.
A PCR screening approach was used to detect the pres-
ence of the desired ligated DNA on the recombinant plas-
mids using the same forward and reverse primers which
were used in amplifying H5 and MDP1 genes, respec-
tively (Table 1). The selected recombinant clones were
further confirmed by restriction enzyme (RE) analysis
and sequencing. Sequencing was carried out using a 48
capillary 3730 DNA Analyzer®  (Applied Biosystems®,
USA) with both the aforementioned primers for H5 and
MDP1 genes as well as the T7 promoter and BGH reverse
universal primers.
Transfection
Cell culture technology was used to test the in vitro
expression of the genes of interest from the cloned plas-
mid. Vero cells (passage 71) were maintained in DMEM
media (Gibco®, England) containing 10% bovine fetal
serum (BFS) (HyClone®) and 1% ampicillin (50 μg/ml)
(Biobasic Inc. ®). The day before transfection, cells were
sub-cultured in a 6-well plate to have 80% confluency on
the day of transfection. Transfection of each plasmid was
performed using Lipofectamine™ 2000 according to the
manufacturer's protocol in which 100 μl of Opti-MEM®
was mixed with 1 μg of desired plasmid. The plate was
incubated and the cells were harvested at 24, 48 and 72
hours post transfection for the detection of protein
expression using SDS-PAGE and Western blotting assays.
Western blotting
Prior to Western blotting, a SDS-PAGE gel was run using
a BenchMark™ pre-stained protein ladder (Invitrogen®,
USA). A BioRad® transblot machine was then used to
transfer the expressed proteins from the SDS-PAGE gel
to a nitrocellulose membrane using a constant current of
15 volt and 60 mA for 90 minutes. To detect the expres-
sion of different proteins, the membrane was incubated
with different primary antibodies. Detection of H5 pro-
tein were performed using rabbit polyclonal antibody
against AIV hemagglutinin A/chicken/Jilin/9/2004
(H5N1) (diluted 1:4000) (AbCam®, USA), whilst expres-
sion of MDP1 with MDP1 monoclonal antibody (1:200)
which was provided by Prof. Dr. Sohkichi Matsumoto.
The membranes were incubated with primary antibody
solution for 1.5 hours at room temperature. The mem-
brane was then incubated in anti-rabbit secondary anti-
body solution (diluted 1:4000) (AbCam®, USA), for 45
minutes at room temperature on a rotary shaker. Finally,
the membrane was incubated in 5 ml of chromogenicJalilian et al. Genetic Vaccines and Therapy 2010, 8:4
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solution (BCIP/NBT substrate for alkaline phosphatase)
until the bands appeared.
Immunization of the chickens with constructed DNA 
vaccines
Briefly, agar plate containing 50 μg/ml ampicillin was cul-
tured using the glycerol stock of target plasmid overnight
at 37°C. A single colony from the plate was cultured in 5
ml of LB broth containing 50 μg/ml ampicillin at 37°C for
8 hours with vigorous shaking. Two ml of the culture was
inoculated in 200 ml of LB broth with 50 μg/ml ampicillin
and shaked vigorously at 37°C for 15 hours. The bacterial
pellet was obtained by centrifuging the culture in 200 ml
centrifuge tubes at 6000 × g for 15 minutes at 4°C. The
plasmids were then extracted using EndoFree®Plasmid
Mega Kit (Qiagen®, Germany). The concentration and
purity of the plasmid were determined using BioRad
smart spec™ 3000 spectrophotometer. The solution was
adjusted to 1 μg/μl and stored at -30°C for immunization
trials. Specific-pathogen-free white Leghorn layer chick-
ens were kept in separate cages for each group and fed
twice a day using commercial chicken pellet while water
was provided ad libitum. Ten days old chickens were
tagged using metal wing tags and divided into five differ-
ent groups with nine chickens in each group, namely H5,
H5 + MDP1, pcDNA3.1 +, PBS and control. The last
three groups were the different categories of negative
control groups consisting of chickens immunized with
parental plasmid alone, saline and left unimmunized,
respectively. Ten days old chickens were immunized with
100 μg of purified plasmid via intramuscular route on the
right pectoral muscle. The chickens in H5 + MDP1 group
were immunized with 100 μg of H5 vaccine on the right
and 100 μg of MDP1 vaccine on the left pectoral muscles.
Two booster immunizations were administered within
two weeks intervals after the first immunization. The first
bleeding was performed via wing vein prior to the first
vaccination and repeated every week post immunization
for 5 weeks. The immunization trials followed interna-
tionally recognized guidelines and approved by animal
care and use committee (Ref No. UPM/FPV/PS/
3.2.1.551/AUP-R51) at the Faculty of Veterinary Medi-
cine, University Putra Malaysia.
Enzyme-linked immunosorbent assay (ELISA)
The sera derived from immunized and control chickens
were subjected to a competitive ELISA test using a quali-
tative ELISA kit (AniGene®, Korea). Briefly, the plates
were pre-coated with recombinant H5 avian influenza
virus antigen (Anigen® H5 AIV Ag). Fifty μl of serum and
50 μl of Mab-HRP were added to the wells and incubated
for 90 minutes at 37°C. The wells were then aspirated and
washed several times to remove the unbounded material.
Following that the substrate solution was added to the
wells and incubated at room temperature for one hour.
The reaction was stopped by adding the stop solution and
a spectrophotometer (450 nm and 620 nm) were used to
read the colorimetric results. The percent inhibition (PI)
value was calculated using, PI value = [1 - (OD sample/
mean OD negative)] × 100 formula in which the samples
with PI value of 50 and more were considered positive.
Hemagglutination inhibition assay (HI)
The HI test was performed using the serum samples
obtained from chickens immunized with different DNA
vaccines. A low pathogenic H5 AIV, [A/MY/Duck/8443/
04 (H5N2)] inactivated in 2-bromoethylenne hydrobro-
mide, titrated at 4 HA/25 μl were used in the test. Briefly,
50 μl of serum was added to the first well and serially
diluted to the 11th well (1:2 to 1:1024). The diluted serum
was then incubated with 25 μl of inactivated H5N2 virus
at room temperature for 20 minutes. Twenty five μl of
0.65% washed chicken RBC was added to all the wells in
plate and incubated for 30 minutes. The test results were
read on a plate reader apparatus and statistically analyzed
using repeated measure ANOVA. The sequence analysis
of the H5 of the H5N2 showed more than 87% similar
with the H5 of H5N1 in use (data not shown).
Table 1: Primers designed for amplification of H5 and MDP1 genes.
Name Type Sequence (5' to 3')
H5 F CCC CAA GCT TAT GGA GAA AAT AGT GCT T
R CCC GGA TCC AAT GCA AAT TCT GCA TTG TAA
MDP1 F CCC AAG CTT ATG AAC AAA GCA GAG CTC
R AAA GGA TCC CTA TTT GCG ACC CCG
F: Forward, R: Reverse
Underlined sequences are the restriction enzyme sitesJalilian et al. Genetic Vaccines and Therapy 2010, 8:4
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Reverse transcription-polymerase chain reaction
The chickens were sacrificed one week after second
booster. The spleen and muscle samples from the injec-
tion site were harvested and used for RT-PCR. Total RNA
extraction of the samples was performed using Trizol® as
described by the manufacturer (Tri Reagent®, Life Tech-
nologies, USA). The extracted RNA was subjected to RT-
PCR using a commercial RT-PCR kit (Promega®, USA).
The PCR mixture and condition were carried out as
described previously by Oveissi et al. with slight modifi-
cations [14]. The extracted RNA was subjected to RT-
PCR using a commercial RT-PCR kit (Promega®, USA).
AMV Reverse Transcriptase High Conc. (15 units/mg)
was used to reverse transcribe 2 μg of respective RNA in
the presence of dNTP's (250 mM), reverse transcriptase
buffer (10 mMTris-HCl, 50 mMKCl, 0.1% TritonR-X-
100), oligo dT primers (0.5 mg) and RNasin Ribonuclease
inhibitor (1 unit/ml). The amplified product was run in
2.5% agarose gel at 70 volt for 45 minutes. The RNA prep-
arations were standardized by RT-PCR for β-Actin and
were free from DNA contamination evaluated by the lack
of signal following non-reverse transcribed RNA using
the same samples and set of primers (Table 2).
Results
Cloning of the H5 and MDP1 gene into the pcDNA3.1 + 
vector
The constructed pcDNA3.1/H5 and pcDNA3.1/MDP1
were transformed into TOP10F' Escherichia coli and the
positive clones were screened using PCR, RE analysis and
sequencing. Digestion with BamHI and HindIII con-
firmed the presence of H5 and MDP1 based on the detec-
tion of the bands of the expected sizes (data not shown).
The sequencing results were checked with the original
sequence of the genes deposited in the GeneBank data-
base using the Blast program of National Institute of Bio-
technology Information (NCBI).
Transient expression of the recombinant plasmids in Vero 
cells
The expressions of H5 and MDP1 genes in Vero cells
were analyzed by SDS-PAGE and Western blot. In West-
ern blot analysis, expressed proteins for H5 (64 kDa) (Fig-
ure 1A) were detected 72 hours after transfection while
the expressed protein for MDP1 (31 kDa) (Figure 1B)
were successfully detected 48 and 72 hours after transfec-
tion.
Enzyme-linked immunosorbent assay
The AIV H5 antibody was successfully detected by a
competitive ELISA starting at 21 days post immunization
on two out of nine chickens immunized with H5 + MDP1
vaccine. At 42 days post immunization eight out of nine
chickens in the above group demonstrated antibody
responses against AIV (Table 3). However, the number of
chickens with antibody responses in group immunized
with H5 alone is lower compared to chickens immunized
with H5 + MDP1. Only five out of nine chickens in the
H5 group demonstrated antibody responses at day 42
post immunization, as shown in Table 3. Chickens from
the negative control groups (pcDNA3.1/MDP1,
pcDNA3.1 and left unimmunized) failed to demonstrate
detectable antibody response (Table 3).
Hemagglutination inhibition assay
The HI titer of the serum samples two weeks after the
first vaccination was zero or very low (≤ 2). All the chick-
ens in the group immunized with H5 vaccine and H5 +
MDP1 vaccines showed HI antibody titer at day 21 post
immunization (Table 4). The chickens in group immu-
n i z e d  w i t h  H 5  +  M D P 1  v a c c i n e s  h a v e  s l i g h t l y  h i g h e r
mean HI titer (3.33 ± 2.42) compared to chickens in the
group immunized with H5 vaccine alone (2.33 ± 0.82).
The increase in the HI titers was recorded in both groups
at two weeks after the first booster and one week after the
second booster. The mean HI titers from chickens immu-
Table 2: Primers for RT-PCR amplification of H5, MDP1 and β actin genes
Name Type Sequence (5' to 3') Length (bp) Product
H5 F TCCAAAGTAAACGGGCAAAG 20 141 bp
R TGYTGAGTCCCCTTTCTTGA 20
MDP1 F TCACACAGAAATTGGGCTCGGA 22 196 bp
R GACGTCGGCTTCACCTTTACTG 22
β actin F GCAGGAGTACGATGAATC 18 140 bp
R AAATAAAGCCATGCCAATC 19Jalilian et al. Genetic Vaccines and Therapy 2010, 8:4
http://www.gvt-journal.com/content/8/1/4
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Figure 1 Western blot analysis of Vero cells transfected with (a), H5 and (b) MDP1 genes. Expression of H5 protein (product of ~ 64 kDa) was 
detected 72 hours after transfection while the expression of MDP1 protein (product of ~ 31 kDa) was detected 48 and 72 hours after transfection. (A) 
Lane M is Prestained™ protein marker (Invitrogen®, USA); Lane 1, 2 and 3 are Vero cells harvested 72, 48 and 24 hours, respectively, after transfection 
of pcDNA3.1 + with H5; Lane 4 is the non-transfected Vero cells. (B) Lane M is Prestained™ protein marker (Invitrogen®, USA); Lane 1, 2 and 3 are Vero 
cells harvested 72, 48 and 24 hours, respectively, after transfection of pcDNA3.1 + with MDP1; Lane 4 is the non-transfected Vero cells.Jalilian et al. Genetic Vaccines and Therapy 2010, 8:4
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nized with H5 + MDP1 vaccines were higher than mean
H I  t i t e r s  r e c o r d e d  f r o m  c h i c k e n s  i m m u n i z e d  w i t h  H 5
vaccine. However, the HI titers for both groups never
exceeded 16. The highest average antibody titers were
detected one week after the second booster, at day 35
post immunization of 13.33 ± 4.13 in chickens immu-
nized with H5 + MDP1 vaccines, as shown in Table 4.
Thus, higher antibody titer were observed in chickens
immunized with H5 + MDP1 vaccines, compared to
chickens immunized with H5 vaccine at day 14, 21, 28
and 35 post vaccination (Table 4). However, the HI titer
increase was not statistically significant. As expected, the
chickens immunized with pcDNA3.1, pcDNA3.1/MDP1,
normal saline and left unimmunized failed to demon-
strate detectable HI titer (Table 4).
Reverse Transcription-Polymerase chain reaction
The ability of the constructed H5 and MDP1 vaccines in
inducing mRNA expression for H5 and MDP1 was stud-
ied using RT-PCR following intramuscular immunization
of the SPF chickens, respectively. Bands of the expected
size (141 bp) indicative of H5 transcripts were detected
from the spleen and muscle samples of the H5 and H5 +
MDP1 immunized groups (Figure 2). Additionally, the
expression of MDP1 constructed plasmid was confirmed
in groups immunized with MDP1 + H5 and MDP1 alone
Table 3: Detection of H5 AIV antibody from serum samples using ELISA.
Group Days post immunization
0 7 14 21 28 35
pcDNA3.1/H5 0/9* 0/9 0/9 2/9 3/9 5/9
pcDNA3.1/H5 
+ pcDNA3.1/
MDP1
0/9 0/9 2/9 4/9 5/9 8/9
pcDNA3.1/
MDP1
0/9 0/9 0/9 0/9 0/9 0/9
pcDNA3.1 + 0/9 0/9 0/9 0/9 0/9 0/9
Negative 
control
0/9 0/9 0/9 0/9 0/9 0/9
* The ratio of positive treatments to the inoculated chickens
Table 4: Mean hemagglutinin inhibition (HI) results of serum samples from immunized chickens.
Group Days post immunization
7 1 42 12 83 5
pcDNA3.1/H5 ND (0/9)* 0.67 ± 1.03 (2/9) 2.33 ± 0.82 (6/9) 5 ± 2.45 (9/9) 10.67 ± 4.13 (9/9)
pcDNA3.1/H5 + 
pcDNA3.1/MDP1
ND (0/9) 0.83 ± 0.98 (2/9) 3.33 ± 2.42 (7/9) 9.33 ± 5.46 (9/9) 13.33 ± 4.13 (9/9)
pcDNA3.1/MDP1 ND (0/9) ND(0/9) ND(0/9) ND(0/9) ND(0/9)
pcDNA3.1 ND (0/9) ND(0/9) ND(0/9) ND(0/9) ND(0/9)
Negative control ND (0/9) ND(0/9) ND(0/9) ND(0/9) ND(0/9)
ND: Not detected
* The ratio of positive treatments to the inoculated chickensJalilian et al. Genetic Vaccines and Therapy 2010, 8:4
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based on the detection of bands of 196 bp in size (Figure
2).
Discussion
Recent advances in molecular biology have raised hopes
of producing more effective DNA vaccines as an alterna-
tive in preventing diseases in a much more specific and
direct manner. Meanwhile, studies on animal models
have provided valuable findings on the potentials of the
DNA vaccine as a new option in vaccine studies and
industry [5]. Prior to this study, MDP1 had been shown to
be a potential DNA vaccine adjuvant in BCG, whereby it
has a unique ability in blocking DNase activity, and con-
sequently decreasing the amount of DNA necessary for
vaccination [20]. Furthermore, studies have showed that
MDP1 is an effective adjuvant for DNA vaccine when
given separately in different plasmids through intraperi-
toneal and intramuscular routes of administrations [20].
In this study we showed that chickens immunized at two
different sites with plasmids containing H5 and MDP1,
respectively, developed higher antibody titer compared to
chickens immunized with H5 alone indicating the adju-
vant effect of MDP1 on AIV DNA vaccine.
The antibody responses to the H5 and H5 + MDP1 vac-
cine were measured using both ELISA and HI test. Mean-
w h i l e ,  s e r u m  s a m p l e s  o b t a i n e d  f r o m  c h i c k e n s  i n  t h e
groups immunized with PBS, pcDNA3.1 + and
pcDNA3.1/MDP1 were negative for antibody titer in
both ELISA and HI test. Chickens immunized with H5 +
MDP1 vaccines were able to produce detectable AIV H5
antibody 1 week earlier compared to chickens immunized
with H5 vaccine alone (Table 3). The mechanisms that
associated with this finding are not know where adminis-
tration of MDP1 facilitate the production of antibody
against H5. Furthermore, eight out of nine chickens in the
H5 + MDP1 immunized group were able to develop
detectable AIV H5 antibody whilst, five out of nine chick-
ens in H5 group were able to show detectable AIV H5
antibody 35 days post immunization.
Based on HI test, the antibody production after immu-
nization was detectable from day 14 and the production
had an increasing pattern for two subsequent bleeding
sessions (Table 3). The mean antibody production of the
group immunized using H5 + MDP1 vaccines was slightly
higher compared to the group immunized with H5 vac-
cine (Table 4). However, the difference was not statisti-
cally significant probably due to high standard deviation.
Probably, a selection of appropriate expression plasmid
construction with optimized codon usages in chickens is
essential in improving the expression and regulates the
delivery of the DNA vaccine for inducing significant anti-
body responses [21]. Furthermore, only nine chickens
were used in a group in the immunization trials.
Amplification of specific regions from RNA genome
was performed using RT-PCR to detect the transcription
of the targeted gene in cells. Previously, Ferstl et al. (2004)
indicated that RT-PCR is an accurate method to study the
expression of desired genes in in vivo experiments [22].
Figure 2 RT-PCR analysis of H5 and MDP1 expression in different tissues obtained from chickens immunized with different DNA vaccines. 
Band of the expected size (141 bp) for H5 in groups immunized with H5 and H5 + MDP1; and band of expected size (196 bp) in groups immunized 
with MDP1 and H5 + MDP1 was detected, respectively.Jalilian et al. Genetic Vaccines and Therapy 2010, 8:4
http://www.gvt-journal.com/content/8/1/4
Page 8 of 9
The spleen and muscle (immunization site) samples of
the chickens immunized with different DNA vaccine con-
structs were extracted and used as templates for PCR and
RT-PCR amplifications. Agarose gel electrophoresis fol-
lowing RT-PCR showed successful expression of H5
mRNA for groups immunized with H5 and H5 + MDP1
vaccines (Figure 2). This finding is consistent with the
results of previous studies suggesting the successful deliv-
ery and presentation of the target gene to the immune
system [14,23-25]. The extracted RNA was analyzed with
PCR amplification only in which no band of the expected
size was detected (data not shown), indicating that the
amplified product from the RT-PCR experiments were
from in vivo transcription of the target genes.
In this study, the intramuscular immunization was per-
formed using endotoxin-free naked H5 cloned in
p c D N A 3 . 1  + ,  r e s u l t e d  i n  t h e  p r o d u c t i o n  o f  a n t i b o d y
against the constructed H5 DNA. This result was consis-
tent with a study performed by Le Gall-Recule' and co-
workers (2002), who found that AIV H7 cloned into an
eukaryotic expression plasmid, pCMV could lead to anti-
body response, using different administration methods
[23]. However, in another study, direct intramuscular
immunization using naked plasmid did not produce the
same HI titer in all the treatment, probably due to the
inaccurate gene delivery system [25]. In this study, a
detectable HI titer was successfully produced from the
direct immunization of H5 and H5 + MDP1 vaccines in
all the treatments (Table 4). Even though the mean HI
titer between chicken immunized with H5 vaccine with
and without MDP1 was not statistically significant, the
HI titers at the different time points during the course of
the experiment between the two groups were found to be
significantly different and had an increasing pattern.
Hence, HI test is more sensitive in detecting H5 antibody
in avian compared to ELISA which is consistent with a
previous study by Bulbot et al. [26].
In this study, the highest HI titer of 13.33 ± 4.13 was
observed in chickens immunized with H5 + MDP1 vac-
cines on day 35 post immunization. Previous studies have
shown, post immunization serum HI titre of 32 and
above results in protective immunity against H5N1 influ-
enza infection or disease in populations [26,27]. Even
though we did not evaluate the constructed vaccines effi-
cacy against viral challenge; but studies showed regard-
less of low antibody titers following immunization with
DNA vaccine, the immunized chickens were protected
against lethal challenge probably due to the cellular
immune response [27-29].
Conclusions
Our study demonstrates the potential of MDP1 as a
genetic adjuvant for H5 DNA vaccine. However, chickens
immunized with H5 + MDP1 vaccines developed the
highest HI titer of 16 although antibody titers between
chickens immunized with H5 with and without MDP1
were not statistically significant. Our future efforts will
concentrate on the analysis of the cellular immune
responses following the immunization using constructed
H5 + MDP1 DNA vaccine.
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